Research Topics
| Steven C CampbellSummaryAffiliation: Cleveland Clinic Foundation Country: USA Publications
| Collaborators
|
Detail Information
Publications
The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosisSteven C Campbell
Edward Hines Jr VA Hospital, Hines, Illinois, USA
Urology 75:1138-43. 2010..The effect of zoledronic acid on patients with pre-existing osteoporosis on ADT, who are highest risk for fracture, has not been adequately studied...- Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapyNirmala Bhoopalam
Edward Hines, Jr Veterans Affairs Hospital, Hines, Illinois 60141, USA
J Urol 182:2257-64. 2009..There are limited data on patients on prolonged androgen deprivation therapy or in Veterans Affairs patients with multiple risk factors for osteoporosis... - Small renal masses: toward more rational treatmentAnil A Thomas
Glickman Urological and Kidney Institute, Cleveland, OH 44195, USA
Cleve Clin J Med 78:539-47. 2011..Renal mass biopsy with molecular profiling will likely allow for more rational treatment in the near future... 
Prostate-sparing cystectomy: has Pandora's box been opened?John C Kefer
Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
Expert Rev Anticancer Ther 7:1003-14. 2007..The concept of PSCx is arguably one of the most controversial topics in the field of bladder cancer today...- Management of the adrenal gland during partial nephrectomyBrian R Lane
Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
J Urol 181:2430-6; discussion 2436-7. 2009..We analyzed initial management and oncological outcomes of adrenal glands after open partial nephrectomy... - Laparoendoscopic single-site radical cystectomy and pelvic lymph node dissection: initial experience and 2-year follow-upJihad H Kaouk
Section of Laparoscopic and Robotic Surgery, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA
Urology 76:857-61. 2010..The development of laparoendoscopic single-site surgery and its application to urothelial malignancy has not been previously evaluated... - Effect of parenchymal volume preservation on kidney function after partial nephrectomyMatthew N Simmons
Section of Urologic Oncology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
J Urol 186:405-10. 2011..We assessed what is to our knowledge a novel method to estimate the percent of functional volume preservation to assess its effect on functional outcomes... - Salvage of local recurrence after primary thermal ablation for small renal massesCarvell T Nguyen
Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, A100 Cleveland, OH 44195, USA
Expert Rev Anticancer Ther 8:1899-905. 2008..We provide, herein, an assessment of the efficacy and limitations of primary thermal ablation and strategies for salvage treatment of local recurrence in this growing patient population... - Surgical salvage of renal cell carcinoma recurrence after thermal ablative therapyCarvell T Nguyen
Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
J Urol 180:104-9; discussion 109. 2008..However, initial data have suggested higher local recurrence rates for ablation compared to partial nephrectomy. We evaluated options for salvage of ipsilateral tumor recurrence after previous ablation... - Current status of prostate-sparing cystectomyJohn C Kefer
Glickman Urological Institute, Cleveland Clinic, Cleveland, OH 44195, USA
Urol Oncol 26:486-93. 2008..Prostate-sparing cystectomy is arguably one of the most controversial topics in the field of urology today... - Choice of operation for clinically localized renal tumorCarvell T Nguyen
Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue A100, Cleveland, OH 44195, USA
Urol Clin North Am 35:645-55; vii. 2008..In all these discussions we assume that a proactive approach to treatment is indicated and desired, recognizing that active surveillance is always an additional option to consider in certain subpopulations such as the elderly or infirm... - Perioperative outcomes with laparoscopic radical cystectomy: "pure laparoscopic" and "open-assisted laparoscopic" approachesGeorges Pascal Haber
Section of Laparoscopic and Robotic Surgery, Glickman Urological Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
Urology 70:910-5. 2007..We retrospectively evaluated the outcomes of these two techniques with a focus on perioperative outcomes and associated morbidity... - Presentation, location and overall survival of pelvic recurrence after radical cystectomy for transitional cell carcinoma of the bladderNivedita Bhatta Dhar
Section of Urologic Oncology, Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
BJU Int 101:969-72. 2008..To evaluate the presentation, location and overall survival of pelvic recurrence after radical cystectomy (RC) for transitional cell carcinoma (TCC) of the bladder... - Risk assessment for occult malignancy in the prostate before radical cystectomyJohn C Kefer
Department of Urology, Loyola University Medical Center, Maywood, Illinois, USA
Urology 66:1251-5. 2005..However, further evaluation of these risk factors in a prospective setting will be required to substantiate these findings and guide clinical decision making in this controversial field... - Surgical resection of renal cell carcinoma after targeted therapyAnil A Thomas
Glickman Urological and Kidney Institute, Cleveland, Ohio 44195, USA
J Urol 182:881-6. 2009..The integration of targeted therapy and surgery requires careful consideration due to the potential for increased perioperative morbidity... - Renal cell carcinomaBrian I Rini
Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, USA
Curr Opin Oncol 18:289-96. 2006.... - Outcomes in patients with urothelial carcinoma of the bladder with limited pelvic lymph node dissectionNivedita Bhatta Dhar
Section of Urologic Oncology, Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
BJU Int 98:1172-5. 2006.... - Nephrectomy induced chronic renal insufficiency is associated with increased risk of cardiovascular death and death from any cause in patients with localized cT1b renal massesChristopher J Weight
Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
J Urol 183:1317-23. 2010..Therefore, we compared overall survival, cancer specific survival and cardiac specific survival in patients undergoing partial or radical nephrectomy for cT1b tumors... - Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary seriesChristopher J Weight
Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, Ohio 44195 0001, USA
Cancer 115:792-9. 2009..The outcome of NC and open radical cystectomy (RC) was evaluated in a contemporary cohort of patients in a tertiary referral setting... - Integration of surgery and systemic therapy in the management of metastatic renal cancerAnil A Thomas
Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Desk A100, 9500 Euclid Avenue, Cleveland, OH 44195, USA
Curr Urol Rep 10:35-41. 2009..Relevant issues in this era relate to the timing of surgery, the role of cytoreduction as systemic therapies become more effective, management of the residual mass, and surgical safety after targeted therapy... - Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinomaAnil A Thomas
Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
J Urol 181:518-23; discussion 523. 2009..We assessed the activity of neoadjuvant sunitinib on primary renal tumors in patients with advanced renal cell carcinoma as well as the feasibility and safety of subsequent surgical resection... - Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapyJuan Barbastefano
Department of Medicine, Cleveland Clinic, Cleveland, OH, USA
BJU Int 106:1266-9. 2010.... - Aggregate lymph node metastasis diameter and survival after radical cystectomy for invasive bladder cancerAndrew J Stephenson
Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
Urology 75:382-6. 2010..The aggregate LN metastasis diameter (ALNMD) may better reflect the burden of metastatic disease and improve the ability to predict recurrence-free (RFS) and overall survival (OS)... - Clinicopathologic features and utility of immunohistochemical markers in signet-ring cell adenocarcinoma of the bladderAnil A Thomas
Glickman Urological and Kidney Institute, The Cleveland Clinic, Cleveland, OH 44195, USA
Hum Pathol 40:108-16. 2009.... - The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapyBrian I Rini
Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Center and Section of Urological Oncology, Glickman Urological Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
J Urol 177:1978-84. 2007..Accomplishing this in the current era of targeted molecular therapies presents unique challenges and opportunities... - Clinical correlates of renal angiomyolipoma subtypes in 209 patients: classic, fat poor, tuberous sclerosis associated and epithelioidBrian R Lane
Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
J Urol 180:836-43. 2008..We investigated the clinical, radiographic and histological characteristics of each angiomyolipoma subtype... - A preoperative prognostic nomogram for solid enhancing renal tumors 7 cm or less amenable to partial nephrectomyBrian R Lane
Glickman Urological Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
J Urol 178:429-34. 2007..We present novel nomograms that predict the likelihood of benign, likely indolent or potentially aggressive pathological findings based only on readily identifiable preoperative factors... - Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or olderBrian R Lane
Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
Cancer 116:3119-26. 2010.... - Elective partial nephrectomy in patients with clinical T1b renal tumors is associated with improved overall survivalChristopher J Weight
Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
Urology 76:631-7. 2010..PN may offer the perfect combination of cancer control and preservation of renal function; therefore we compared overall and cancer-specific survival in patients treated for cT1b renal masses... - Targeted molecular therapy for renal cell carcinomaBrian R Lane
Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
Urology 69:3-10. 2007 - Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapyBrian R Lane
Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA
Cancer 116:2967-73. 2010..Although multimodal treatment paradigms for UTUC are under-developed, this has important implications on patients' ability to receive cisplatin-based combination chemotherapy (CBCC)... - Current trends in the management of bladder cancerAmit R Patel
Glickman Urological and Kidney Institute, The Cleveland Clinic, Ohio 44195, USA
J Wound Ostomy Continence Nurs 36:413-21; quiz 422-3. 2009..Newer therapies involving novel molecular-targeted agents provide hope for the future for patients with metastatic disease... - Screening for urologic malignancies in primary care: pros, cons, and recommendationsAndrew J Stephenson
Section of Urologic Oncology, Glickman Urological Institute, Cleveland Clinic, Cleveland, OH 44195, USA
Cleve Clin J Med 74:S6-14. 2007.... - Laparoscopic radical cystectomyMonish Aron
Section of Laparoscopic and Robotic Surgery, Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
BJU Int 100:455-76. 2007 - Staging of renal cell carcinoma: past, present, and futureCarvell T Nguyen
Glickman Urological Institute, Cleveland Clinic Foundation, OH 44195, USA
Clin Genitourin Cancer 5:190-7. 2006..Finally, a glimpse into the future of staging of RCC will be offered with a discussion of integrated staging and prognostic systems... - Laparoscopic radical cystectomy: current status, outcomes, and patient selectionBrian H Irwin
Department of Urology, Center for Laparoscopic and Robotic Surgery, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH 44195, USA
Curr Treat Options Oncol 10:243-55. 2009.... - Renal cell carcinomaBrian I Rini
Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA
Lancet 373:1119-32. 2009..Targeted drugs, including inhibitors of the vascular endothelial growth factor and mammalian target of rapamycin pathways, have shown robust effectiveness and offer new therapeutic options for the patients with metastatic disease... - Gonadal vein tumor thrombus in metastatic renal cell carcinomaAnil A Thomas
Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
Urology 73:1229-30. 2009..We present a case of a patient with unresectable metastatic renal cell carcinoma invading the gonadal vein, who was initially treated with targeted molecular therapy... - The paradigm shift in renal mass biopsySteven C Campbell
Section of Urological Oncology, Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA
Clin Adv Hematol Oncol 6:253-4, 258. 2008 - Renal mass biopsy--a renaissance?Brian R Lane
Glickman Urological Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
J Urol 179:20-7. 2008.... - Renal medullary carcinoma and ABL gene amplificationLijo Simpson
Department of Medicine, Illinois Masonic Medical Center, Maywood, Illinois, USA
J Urol 173:1883-8. 2005..The use of thalidomide or newer anti-angiogenesis agents should be considered for advanced disease. The role of ABL amplification with respect to etiology and as a therapeutic target should be investigated further... - Performance of the chronic kidney disease-epidemiology study equations for estimating glomerular filtration rate before and after nephrectomyBrian R Lane
Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
J Urol 183:896-901. 2010..We compared the estimated glomerular filtration rate using several serum creatinine based formulas against the measured rate based on (125)I-iothalamate clearance to determine which most accurately reflects the rate in this setting... - Adult cystic nephroma and mixed epithelial and stromal tumor of the kidney: clinical, radiographic, and pathologic characteristicsBrian R Lane
Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
Urology 71:1142-8. 2008..Clinical and radiographic data regarding these lesions are sparse, especially with respect to factors providing clinical suspicion for CN or MEST...